On March 13th, AstraZeneca China announced that the State Food and Drug Administration officially approved AstraZeneca's diabetes treatment innovative drug Andatang (common name: dapagliflozin) as a monotherapy for type 2 Adults with diabetes improve glycemic control, and dapagliflozin will be the first sodium-glucose co-transporter 2 (SGLT2) inhibitor listed in China.
It is reported that with a new non-insulin-dependent mechanism of action, dapagliflozin can reduce renal glucose reabsorption through high-selective inhibition of sodium-glucose co-transporter 2 (SGLT2), and lower blood sugar by direct glucose excretion in the urine. At the secondary endpoint of the dapagliflozin study, weight loss and blood pressure were also found.
Dr. Ji Linong, Principal Investigator of DagleyNet China's Registered Research and Peking University People's Hospital, pointed out: "The treatment of type 2 diabetes has been mostly controlled by insulin-dependent mechanisms, and dapagliflozin is through a non-insulin-dependent mechanism. It plays a role in reducing blood sugar by reducing glucose in the kidneys and directly discharging sugar from the urine, providing a new choice for doctors to treat type 2 diabetes. Since Daglibine was the first in the world, we have been expecting it. Being able to come to China as soon as possible, I believe that with the listing of Daglipin in China, it will also enable more Chinese patients with type 2 diabetes to gain more clinical benefits and further improve the control rate and clinical outcome of type 2 diabetes in China. ."
Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.zhongzhinanlighting.com